Table 4.

Main characteristics of studies including patients with cirrhosis and acute upper gastrointestinal bleeding

Ref.	Patients (n)	Patients with MWS bleeding (n)	Cirrhotic patients with MWS bleeding (n)	Patients with MWS received endoscopic treatment (n)	Endoscopic treatment modalities (n)	Failure to control initial overt bleeding, n (%)	Rebleeding, n (%)	Mortality during follow-up, n (%)
Paquet et al[30]	339	55	53	53	ES (polidocanol)	0	NR	NR
Schuman et al[31]	79	42	14	4	EI; BICAP EC	0	NR	3/42 (7%)
Higuchi et al[32]	37	37	11	37	EBL	0	1/37 (2.7%)	1/37 (2.7%)
Lecleire et al[33]	218	218	7	56	EBL: 27; EI + HC: 29	0	5/56 (9%) (Hemoclips + Epinephrine)	0
González-González et al[22]	160	18	18	0	EI: 0; BICAP EC : 0	NR	NR	22/160 (13.8%)

ES: Esophageal sclerotherapy; EI: Epinephrine injection; EC: Electrocoagulation; NR: Not reported; EBL: Endoscopic band ligation; HC: Hemoclips.